Suppliers / Sionc Pharmaceuticals

Sionc Pharmaceuticals

India 2 duplicate records merged Updated 9 July 2026

Sionc Pharmaceuticals is an API manufacturer based in India. It holds 2 active US drug master files and one valid CEP across a filed portfolio of 6 molecules. Its GMP standing is certified by MFDS (Korea) and EMA. Customs aggregates show $5.8M of exports covering 103 molecules to 27 destinations in 2025.

2
active US DMFs
1
valid CEPs
2
registered plants
5
filings across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
EU GMP
1 of 1 confirmed
Sources: EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Registered plants

Site FDA FEI
Visakhapatnam, India Not on file
Thanam (Village), IDA Parawada, Visakhapatnam-531021, Andhra Pradesh, India Not on file

What they file, and where

Molecule Regulators Docs
Vigabatrin EDQM, US FDA 3
Bendamustine SFDA (Saudi Arabia) 1
Cladribine SFDA (Saudi Arabia) 1
Clofarabine SFDA (Saudi Arabia) 1
Nelarabine SFDA (Saudi Arabia) 1
Palbociclib SFDA (Saudi Arabia) 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
CDSCO (India) 5 None
MFDS (Korea) None 2
EMA None 1

Scale

Year Revenue Exports Destinations
2026 YTD Not reported $1.8M 15
2025 Not reported $5.8M 27
2024 Not reported $7.2M 19
2023 Not reported $7.3M 23

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. Sionc Pharmaceuticals comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Customs aggregates
Export values, molecule and destination counts